Renal denervation is a minimally invasive method of treating hypertension that lowers blood pressure by reducing nerve activity. This procedure uses radiofrequency ablation to burn away the damaged renal artery tissues and avoid cardiac blockage. Because of this procedure, neural activity is reduced, which in turn lowers blood pressure.

The market value of renal denervation in 2021 was USD 219.49 million and will be USD 4743.13 million by 2030 at a 40.7% CAGR.

A major factor boosting market growth is the significant rise in the prevalence of lifestyle diseases like hypertension, which is caused by increased sedentary and stressful lifestyles, alcoholic and tobacco use, unhealthy eating habits, and an escalating geriatric population.

Market Dynamics

Drivers

The renal denervation market has grown due to changes in lifestyle that cause resistant hypertension and an increase in hypertension prevalence. Furthermore, the prevalence of hypertension has increased significantly in recent years, causing fluctuations in blood pressure, but if it remains high for a large period of time, it may harm one's heart and cause health concerns. According to the World Health Organization, hypertension will affect approximately 1.28 billion people aged 30 to 79 by 2021. An increase in hypertension cases is expected to drive demand for renal denervation devices during the forecasted period.

The Centers for Disease Control & Prevention reported that more than 360,000 Americans died in 2013 due to high blood pressure. The prevalence of hypertension has risen from 17,307 per 100,000 people in 1990 to 20,525 per 100,000 people in 2015. However, renal denervation therapy is effective in lowering blood pressure. As a result, the benefits of these therapies, such as permanent effect, reduced treatment time, and increased safety, drive market growth. Furthermore, advances in renal denervation devices will drive the market.

Restraints

One of the major factors limiting the demand for renal denervation is the risk of infection following surgery. Infections in the patient's body can result from any type of surgery that involves skin cuts, incisions, or other treatments.

Opportunity

Growing patient's preference for minimally invasive procedures

 A minimally invasive procedure is used to treat hypertension. An ultrasound-based renal denervation device sends an ultrasound inside the renal artery wall to disrupt nerve impulse transmission and lower blood pressure. This process improves efficiency, paving the way for the renal denervation market's future.

Market Segmentation

By Technology

On the basis of technology, the market is segmented into radiofrequency, ultrasound, and micro-infusion. The ultrasound sector was the biggest market in 2021. The ultrasound-based renal denervation devices use ultrasound to minimally invasively ablate nerves in the walls of the renal arteries. By interfering with nerve impulse transmission to and from the kidney, it lowers blood pressure. High-frequency sound waves from ultrasound energy evaporate neurons without coming into direct contact with tissues, limiting renal artery injury. 

By End-User

On the basis of end-user, the market is segmented into hospitals, specialty clinics, and others. In 2021 the Hospitals segment led the overall market with the largest revenue share. This industry is expanding as a result of the government's increased funding for the development of multiple specialty hospitals to address the rise of deadly diseases. In addition, professional doctors, nurses, surgeons, and other healthcare providers now make up the majority of the hospital staff, as opposed to the past when volunteers or members of founding religious orders performed the majority of these tasks.

Regional Analysis

In 2021, Asia Pacific led the entire regional market with a significant revenue share. There are many potential growth opportunities for the Market participants in Asia-Pacific because of the region's high prevalence of resistant hypertension, multiple unmet medical needs for hypertension treatment, greater awareness of cutting-edge technologies like renal denervation systems, and numerous untapped medical needs for hypertension therapy. Consequently, the local market would experience significant growth over the ensuing years.

Key Players 

· Abbott Laboratories

· Ablative Solutions, Inc

· Medtronic plc

· Cardiotonic Ltd

· Johnson & Johnson

· Boston Scientific Corporation

· ReCor Medical, Inc

· Terumo Corporation

· Mercator MedSystems, Inc

· Renal Dynamics Limited

The market value of renal denervation in 2021 was USD 219.49 million and will be USD 4743.13 million by 2030 at a 40.7% CAGR. The market for renal denervation has expanded as a result of the increased risk of hypertension brought on by factors including excessive alcohol intake, sedentary lifestyles, smoking, and fast food consumption.

Related Reports:

Endovascular Aneurysm Repair Market Report - The global endovascular aneurysm repair market will witness a robust CAGR of 5.8%, valued at $3.03 billion in 2021, expected to appreciate and reach $5.03 billion by 2030, confirms Strategic Market Research.